The effect of 5-Aminolevulinic Acid to diagnose the upper urinary tract tumor with retrograde intra-renal ureteroscopy
Not Applicable
Recruiting
- Conditions
- pper tract urinary tumor UTUC
- Registration Number
- JPRN-UMIN000035166
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
The following are exclusion criteria 1) patient with positive imaging finding and positive urinary cytology 2) patient with porphyrine allegery 3) patient with 5ALA allegery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitivity
- Secondary Outcome Measures
Name Time Method Specifity
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 5-aminolevulinic acid's fluorescence in upper urinary tract tumor detection during retrograde intra-renal ureteroscopy?
How does 5-aminolevulinic acid compare to standard-of-care imaging techniques in diagnosing upper tract urothelial carcinoma (UTUC)?
Which biomarkers correlate with enhanced 5-aminolevulinic acid fluorescence response in upper urinary tract tumor diagnosis?
What adverse events are associated with 5-aminolevulinic acid administration during retrograde intra-renal ureteroscopy for UTUC detection?
Are there combination approaches involving 5-aminolevulinic acid and other photodynamic agents for improved upper urinary tract tumor visualization?